Piperacillin
Bone Marrow Suppression
European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Bone Marrow Suppression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
Tazobactam European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | BB |
Vancomycin European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | BB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | B |
FILGRASTIM Fred Hutchinson Cancer Center | Phase 2 | B |
View all 27 →
Same molecule, other indications
Piperacillin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →